Cancer Biology


Cancer remains one of the leading causes of morbidity and mortality worldwide. A diverse array of chemical and biological compounds has been developed to target cancer cells through various mechanisms, ranging from direct cytotoxicity to modulation of specific molecular pathways.
Traditional chemotherapeutic agents, such as alkylating agents, antimetabolites, topoisomerase inhibitors, and mitotic inhibitors, exert their effects primarily by interfering with DNA replication or cell division, thereby preferentially targeting rapidly proliferating tumor cells. Targeted therapy agents, such as tyrosine kinase inhibitors and proteasome inhibitors, selectively suppress oncogenic signaling pathways, thereby offering enhanced specificity and reduced systemic toxicity. Immunotherapeutic agents, such as immune checkpoint inhibitors, harness the immune system to recognize and eliminate cancer cells. In addition, epigenetic modulators, DNA repair inhibitors, and angiogenesis-targeting compounds constitute novel therapeutic strategies.
-
A1094 tumor protein p53 binding protein fragment [Homo sapiens]/[Mus musculus]Summary: P53 binding protein fragment -
A1097 ubiquitin specific protease 3 fragmentSummary: Deubiquitinates uH2A/uH2B -
B3701 FPH1 (BRD-6125)1 CitationSummary: Hepatocyte functional proliferation enhancer -
B8914 Pseudobufarenogin -
A1107 Cdk2/Cyclin Inhibitory Peptide ISummary: Cell division protein kinase 2 -
A1109 Endostatin (84-114)-NH2 (JKC367)Summary: Angiogenesis inhibitor -
A1118 S6 Kinase Substrate Peptide 32Summary: Measures the activity of kinases that phosphorylate ribosomal protein S6. -
A1133 Epidermal growth factor receptor (994-1002) acetyl/amideSummary: EGF-family receptor -
A1146 Histone-H2A-(107-122)-Ac-OHSummary: Histone-H2A peptide -
C8147 DaunomycinoneSummary: Daunomycinone (NSC-109351) is a metabolite of Daunomycin.

